Abstract
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Highlights
The search for safe and effective drugs to treat schizophrenia is hindered by the complex nature of this disorder, which is known to involve multiple brain neurotransmitters.[1]
The basic hypothesis for our translational approach was that enhancement of anandamide signaling by administration of cannabidiol should result in an improvement of psychotic symptoms
Our results provide evidence that the non-cannabimimetic constituent of marijuana, cannabidiol, exerts clinically relevant antipsychotic effects that are associated with marked tolerability and safety, when compared with current medications
Summary
The search for safe and effective drugs to treat schizophrenia is hindered by the complex nature of this disorder, which is known to involve multiple brain neurotransmitters.[1] Among them are the endogenous cannabinoids, a family of lipid messengers that target the same cell surface receptors engaged by D9-tetrahydrocannabinol in marijuana.[2] Because D9-tetrahydrocannabinol and other direct-acting cannabinoid agonists can induce psychotic symptoms both in healthy volunteers[3,4,5] and schizophrenic patients,[6,7] it has been suggested that hyperactivity of the endocannabinoid system might contribute to psychotic states.[8,9] This idea has fueled two large-scale clinical trials with CB1-type cannabinoid receptor antagonists in schizophrenia, which yielded, negative results.[10,11] A diametrically opposite view — namely that certain components of the endocannabinoid system might have a protective role in schizophrenia — was suggested by studies with antipsychotic-naıve schizophrenic patients, in which it was found that the symptom intensity experienced by these subjects was negatively correlated with cerebrospinal levels of anandamide,[12,13] an endocannabinoid transmitter known to be involved in the regulation of pain, mood and cognition.[14] Consistent with these clinical observations, animal experiments have shown that pharmacological blockade of anandamide degradation attenuates, rather than enhances, psychotic-like behaviors induced in rodents by amphetamine and phencyclidine.[15,16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
